NCT00441766 - Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain | Biotech Hunter

Enrollment

213

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Irritable Bowel Syndrome

Interventions

DRUG

AGN 203818

Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks

DRUG

AGN 203818

Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks

DRUG

AGN 203818

Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks

DRUG

placebo

Part A: placebo capsule every 12 hours for 4 weeks

Trial Locations (1)

Orange